Novartis’ Panobinostat Review Pits Progression-Free Survival Against Toxicities
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee will also consider whether appropriate dose was selected for Phase III trial of the oral deacetylase inhibitor in patients with relapsed multiple myeloma.